Ocugen's OCU410ST Gene Therapy Shows 54% Reduction in Stargardt Disease Progression in Phase 1 Trial
Key Insights
Ocugen's OCU410ST modifier gene therapy demonstrated a 54% reduction in atrophic lesion growth in treated eyes compared to untreated eyes over 12 months in Phase 1 GARDian1 trial results published in Nature Eye.
All treated patients either stabilized or improved in visual acuity, with treated eyes gaining an average of 4.5 letters compared to a 1.5 letter decline in untreated fellow eyes.
The therapy showed a favorable safety profile with no drug-related serious adverse events, supporting advancement to the ongoing Phase 2/3 GARDian3 trial.
Ocugen announced the publication of positive Phase 1 GARDian1 trial results for OCU410ST, its novel modifier gene therapy for Stargardt disease (search), in the peer-reviewed journal Nature Eye. The study demonstrated significant structural and functional benefits in patients with this inherited form of macular degeneration (search), for which no approved treatments currently exist.
Trial Design and Patient Population
The GARDian1 trial was a multicentre, open-label, 3+3 dose escalation study involving nine patients with Stargardt disease (search) type 1 (STGD1). Participants received a single 200 μl subretinal injection of OCU410ST in their worse-seeing eye, with doses ranging from low (3.75 × 10¹⁰ vg/mL) to high (2.25 × 10¹¹ vg/mL). Key eligibility criteria included patients aged 18-65 years with biallelic ABCA4 (search) variants, early to advanced bull's eye maculopathy, and best corrected visual acuity ≥50 ETDRS letters.
Significant Reduction in Disease Progression
Among six patients with gradable Fundus Auto Fluorescence images, OCU410ST demonstrated remarkable efficacy in slowing disease progression. Atrophic lesion growth was reduced by 54% in treated eyes, with progression of 0.55 ± 0.27 mm² compared to 1.19 ± 0.31 mm² in untreated fellow eyes over 12 months.
The annual lesion expansion rate was 50% slower in treated eyes (0.10 ± 0.039 mm/year) versus untreated eyes (0.19 ± 0.026 mm/year). Notably, the rate in treated eyes fell below published natural history rates of 0.14-0.18 mm/year, indicating meaningful disease modification.
Visual Function Improvements
Among six BCVA-evaluable patients without confounders, treated eyes showed substantial functional benefits. Treated eyes improved by +4.5 ± 2.20 ETDRS letters at 12 months, compared to a decline of -1.5 ± 2.33 letters in untreated fellow eyes, yielding a +6-letter gain. Remarkably, 100% of treated eyes either stabilized (±4 letters) or improved (≥5 letters) in visual acuity.
Safety Profile
The therapy demonstrated a favorable safety profile with no drug-related serious adverse events or adverse events of special interest observed. Treatment-emergent adverse events unrelated to OCU410ST occurred in 8 of 9 patients (89%), totaling 30 events that were predominantly mild (73% Grade 1, 27% Grade 2) and attributable to procedural effects, underlying disease progression, or comorbidities.
Novel Therapeutic Approach
OCU410ST utilizes an AAV5 delivery platform to deliver the RORA (search) (RAR-Related Orphan Receptor A) gene to the retina. By restoring nuclear hormone receptor signaling, the therapy addresses multiple pathophysiological pathways linked to Stargardt disease (search), including lipofuscin formation, oxidative stress, complement activation, inflammation, and photoreceptor survival networks, independent of the underlying ABCA4 (search) genotype.
"This publication in Eye validates the scientific approach and clinical promise of OCU410ST as a modifier gene therapy for Stargardt disease (search)," said Dr. Huma Qamar, Chief Medical Officer at Ocugen. "The Phase 1 GARDian1 trial demonstrated convergent functional and structural benefits. This represents a paradigm shift from any other approaches, including oral or mutation-constrained replacement approaches, to an agnostic modification strategy that can potentially benefit patients regardless of their underlying ABCA4 (search) mutation with a potential single gene therapy for life."
Clinical Context and Unmet Need
Stargardt disease (search) is the most common form of inherited macular degeneration (search), affecting more than 100,000 people in the United States and Europe combined. The disease is characterized by progressive central vision loss due to photoreceptor degeneration caused by toxic lipofuscin accumulation in the retinal pigment epithelium. Currently, no approved treatment exists for this devastating condition, representing a critical unmet medical need.
Dr. Arshad M. Khanani, lead author of the publication and Director of Clinical Research at Sierra Eye Associates, noted: "The consistent benefits observed across both structural and functional endpoints including slowing atrophic lesion progression and stabilization or improvement in visual acuity highlight the potential of this modifier gene therapy platform approach to transform treatment outcomes for patients with Stargardt disease (search), who currently have no disease-modifying options available."
Regulatory Pathway
The Phase 2/3 GARDian3 trial is progressing ahead of schedule with anticipated enrollment completion in the first quarter of 2026. Ocugen remains positioned for Biologics License Application (BLA) filing in the first half of 2027, aligned with its strategy to advance three regulatory submissions in three years.